Mineralys Therapeutics, Inc.
MLYS
$14.89
$0.2751.88%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 28.36M | 25.78M | 23.82M | 20.65M | 18.30M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 203.07M | 201.49M | 192.40M | 168.35M | 134.51M |
Operating Income | -203.07M | -201.49M | -192.40M | -168.35M | -134.51M |
Income Before Tax | -190.77M | -188.51M | -177.81M | -153.25M | -119.67M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -190.77 | -188.51 | -177.81 | -153.25 | -119.67 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -190.77M | -188.51M | -177.81M | -153.25M | -119.67M |
EBIT | -203.07M | -201.49M | -192.40M | -168.35M | -134.51M |
EBITDA | -203.01M | -201.44M | -192.36M | -140.61M | -80.51M |
EPS Basic | -3.57 | -3.74 | -3.64 | -3.27 | -2.71 |
Normalized Basic EPS | -2.23 | -2.33 | -2.28 | -2.05 | -1.69 |
EPS Diluted | -3.57 | -3.74 | -3.64 | -3.27 | -2.71 |
Normalized Diluted EPS | -2.23 | -2.33 | -2.28 | -2.05 | -1.69 |
Average Basic Shares Outstanding | 218.39M | 202.29M | 194.03M | 184.17M | 174.28M |
Average Diluted Shares Outstanding | 218.39M | 202.29M | 194.03M | 184.17M | 174.28M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |